仟源医药 (300254)
SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 25610.86
- Circulating A-Shares(W): 22437.79
- Earnings Per Share(RMB): 0.0922
- Net Assets Per Share(RMB): 1.1485
- Operating Revenue(W RMB): 61147.34
- Total Profit(W RMB): 7736.93
- Net Profit Attributable to Parent(W RMB): 2232.74
- Net Profit Growth Rate(%): -49.43
- Weighted Return on Equity(%): 8.1000
- Operating Cash Flow Per Share(RMB): 0.2940
- Undistributed Profit Per Share(RMB): -0.8542
- Capital Reserve Per Share(RMB): 1.1785
2. Main Business
The main business covers:
- Research, production, and sales of pharmaceuticals
- Research, production, and sales of health foods
- Medical health services such as medical diagnosis and gene preservation
- Commercial services
3. Company Basic Information
- Company Name: Shanxi C and Y Pharmaceutical Group Co., Ltd.
- Listing Date: 2011-08-19
- Industry: Pharmaceutical Manufacturing
- Address: No. 1378, Heng'an Street, Economic and Technological Development Zone, Datong City, Shanxi Province
- Website: www.cy-pharm.com
- Company Profile: The company was established through the lawful overall change of Qianyuan Co., Ltd. On May 16, 2010, all shareholders of Qianyuan Co., Ltd., as promoters, jointly signed the "Promoter Agreement" for the establishment of the company, unanimously agreeing to convert the audited net assets of RMB 115,464,427.25 as of April 30, 2010, into 100 million shares at a conversion ratio of 1.1546442725:1, with the balance of RMB 15.4644 million credited to capital reserve. On May 31, 2010, Lixin Certified Public Accountants Co., Ltd. issued the "Capital Verification Report" (Xin Hui Shi Bao Zi (2010) No. 24365). On June 6, 2010, after approval and registration by the Datong City Administration for Industry and Commerce in Shanxi Province, the company obtained the "Business License of Enterprise Legal Person" with registration number 140200400002021.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shandong Sanzu Private Securities Investment Fund Management Co., Ltd. - Sanzu Sky No.1 Private Securities Investment Fund | Private Securities Investment Fund | 311.49 | 1.38 |
| 2 | Shandong Sanzu Private Securities Investment Fund Management Co., Ltd. - Sanzu Sky No.5 Private Securities Investment Fund | Private Securities Investment Fund | 264.04 | 1.17 |
| 3 | MORGAN STANLEY &CO.INTERNATIONAL PLC. | QFII | 151.85 | 0.67 |
| 4 | ChinaAMC Dingrong Bond Securities Investment Fund Class A | Fund | 3.39 | 0.02 |
| 5 | ChinaAMC Ruipan Taimao Hybrid Securities Investment Fund Class A | Fund | 2.23 | 0.01 |
| 6 | Western Lead Quantitative Select One-Year Holding Hybrid Securities Investment Fund Class A | Fund | 2.22 | 0.01 |
| 7 | ChinaAMC PanTai Hybrid Securities Investment Fund (LOF) Class A | Fund | 1.97 | 0.01 |
| 8 | ChinaAMC Ruipan Taixing Hybrid Securities Investment Fund Class A | Fund | 0.57 | 0.00 |
| 9 | Everbright Baodexin Quantitative Core Securities Investment Fund Class A | Fund | 0.47 | 0.00 |
| 10 | ChinaAMC Wenjin Zengyi One-Year Holding Hybrid Securities Investment Fund Class A | Fund | 0.44 | 0.00 |
5. Concept Sectors
- Infant and Child Concept
- Elderly Care Concept
- Gene Concept
- Vitamins
- Generic Drugs
- NMN Concept
- Hepatitis Concept
- Innovative Drugs
- Micro-Cap Stocks
- Being Acquired
- Dispersed Shareholding
- Individual Shareholding
- Small-Cap Non-Marginable
- Micro-Cap Selection
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information